The Prognostic Significance of Pretreatment Serum CEA Levels in Gastric Cancer: a Meta-analysis Including 14651 Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 17

PMID 25879931

Citations 61

Authors

Kai Deng

Li Yang

Bing Hu

Hao Wu

Hong Zhu

Chengwei Tang

Affiliations

Soon will be listed here.

Abstract

Background: Carcinoembryonic antigen (CEA) is commonly used as a serum tumor marker in clinical practice; however, its prognostic value for gastric cancer patients remains uncertain. This meta-analysis was performed to assess the prognostic value of CEA and investigate CEA as a tumor marker.

Methods: PubMed, EMBASE and other databases were searched for potentially eligible studies. Forty-one studies reporting the prognostic effect of pretreatment serum CEA expression in gastric cancer patients were selected. Data on 14651 eligible patients were retrieved for the meta-analysis. Based on the data extracted from the available literature, the hazard ratio (HR) and 95% confidence interval (CI) for an adverse prognosis were estimated for gastric cancer patients with elevated pretreatment serum levels of CEA (CEA+) relative to patients with normal pretreatment CEA levels (CEA-).

Results: The CEA+ patients had a significantly poorer prognosis than the CEA- patients in terms of overall survival (OS: HR 1.716, 95% CI 1.594 - 1.848, P< 0.001), disease-specific survival (DSS: HR 1.940, 95% CI 1.563 - 2.408, P< 0.001), and disease-free survival (DFS: HR 2.275, 95% CI 1.836 - 2.818, P< 0.001). Publication bias and an influence of different cut-off values were not observed (all P> 0.05). In the pooled analyses of multivariate-adjusted HRs, the results suggested that pretreatment serum CEA may be an independent prognostic factor in gastric cancer (OS: HR 1.681, 95% CI 1.425 - 1.982; DSS: HR 1.900, 95% CI 1.441 - 2.505; DFS: HR 2.579, 95% CI 1.935 - 3.436).

Conclusion/significance: The meta-analysis based on the available literature supported the association of elevated pretreatment serum CEA levels with a poor prognosis for gastric cancer and a nearly doubled risk of mortality in gastric cancer patients. CEA may be an independent prognostic factor for gastric cancer patients and may aid in determining appropriate treatment which may preferentially benefit the CEA+ patients.

Citing Articles

Carcinoembryonic antigen trajectory predicts pathological complete response in advanced gastric cancer after neoadjuvant chemotherapy.

Chen Y, Liu D, Wei K, Lin Y, Wang Z, Sun Q Front Oncol. 2025; 15:1525324.

PMID: 39995833 PMC: 11847669. DOI: 10.3389/fonc.2025.1525324.

The Advancement Stage of Gastric Cancer and the Levels of CEA and Ca19-9 in Serum and Peritoneal Lavage.

Bak M, Wojciech M, Pielech A, Holka S, Zawadzki M, Murawa D Biomedicines. 2024; 12(11).

PMID: 39595150 PMC: 11592263. DOI: 10.3390/biomedicines12112584.

Novel immunotherapeutic approaches in gastric cancer.

Yang M, Lin W, Huang J, Mannucci A, Luo H Precis Clin Med. 2024; 7(4):pbae020.

PMID: 39397869 PMC: 11467695. DOI: 10.1093/pcmedi/pbae020.

Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.

Zheng H, Zhang L, Lv C, Xu B, Lin J, Zheng C BMC Cancer. 2024; 24(1):1188.

PMID: 39333952 PMC: 11438086. DOI: 10.1186/s12885-024-12937-9.

Prognostic value and predictive model of tumor markers in stage I to III gastric cancer patients.

Sun A, Zhang X, Huang Y, Chen L, Wang Q, Jiang X World J Clin Oncol. 2024; 15(8):1033-1047.

PMID: 39193154 PMC: 11346068. DOI: 10.5306/wjco.v15.i8.1033.

References

Thomas S, Tong Z, Stebe K, Konstantopoulos K . Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology. 2009; 46(3):207-25. DOI: 10.3233/BIR-2009-0534. View

Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J . Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2001; 16(3-4):105-10. PMC: 3851416. DOI: 10.1155/2000/595492. View

Staab H, Anderer F, Brummendorf T, Hornung A, Fischer R . Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. Br J Cancer. 1982; 45(5):718-27. PMC: 2011025. DOI: 10.1038/bjc.1982.113. View

Shimizu K, Ueda Y, Yamagishi H . Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005; 8(4):214-9. DOI: 10.1007/s10120-005-0337-4. View

Hartgrink H, Jansen E, van Grieken N, van de Velde C . Gastric cancer. Lancet. 2009; 374(9688):477-90. PMC: 4613761. DOI: 10.1016/S0140-6736(09)60617-6. View

Konstantopoulos K, Thomas S . Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 2009; 11:177-202. DOI: 10.1146/annurev-bioeng-061008-124949. View

Gaspar M, Arribas I, Coca M . Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001; 22(5):318-22. DOI: 10.1159/000050633. View

Louhimo J, Kokkola A, Alfthan H, Stenman U, Haglund C . Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer. 2004; 111(6):929-33. DOI: 10.1002/ijc.20321. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

10.

Park H, Rha S, Kim H, Hyung W, Park J, Chung H . A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Oncology. 2011; 80(1-2):142-50. DOI: 10.1159/000328507. View

11.

Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S . Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012; 107(2):275-9. PMC: 3394986. DOI: 10.1038/bjc.2012.262. View

12.

Kanetaka K, Ito S, Susumu S, Yoneda A, Fujita F, Takatsuki M . Clinical significance of carcinoembryonic antigen in peritoneal lavage from patients with gastric cancer. Surgery. 2013; 154(3):563-72. DOI: 10.1016/j.surg.2013.03.005. View

13.

Duraker N, Celik A . The prognostic significance of preoperative serum CA 19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001; 76(4):266-71. DOI: 10.1002/jso.1044. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Kim D, Kim H, Shim J, Park C, Kim S, Kim Y . Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients. J Surg Oncol. 2000; 74(3):185-92. DOI: 10.1002/1096-9098(200007)74:3<185::aid-jso4>3.0.co;2-0. View

16.

Li F, Li S, Wei L, Liang X, Zhang H, Liu J . The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers. 2013; 18(7):632-7. DOI: 10.3109/1354750X.2013.840800. View

17.

Zhang Y, Li Y, Chen C, Peng C . Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy. Hepatogastroenterology. 2010; 56(96):1750-4. View

18.

Ye X, Guo A, Yin P, Cao X, Chang J . Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancer. Med Oncol. 2014; 31(7):61. DOI: 10.1007/s12032-014-0061-1. View

19.

Cetin B, Atalay C, Aslan S, Babacan B, Hatipoglu C, Akinci M . Peritoneal carcinoembryonic antigen level for predicting locoregional and distant spread of gastric cancer. Surg Today. 2005; 35(11):919-24. DOI: 10.1007/s00595-005-3057-9. View

20.

Nakata B, Chung K, Kato Y, Yamashita Y, Inui A, Arimoto Y . Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer. 1998; 77(11):1820-4. PMC: 2150317. DOI: 10.1038/bjc.1998.302. View